Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Coronary Restenosis, Myocardial Infarction, Stent Thrombosis, Vascular Disease
Interventions
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Completed Not applicable Interventional Results available

EXCEL Clinical Trial

NCT01205776
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Huntsville, Alabama • Mesa, Arizona • Hot Springs, Arkansas + 40 more
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more